ENDYVE | ENgineering DYnamic ViscoElasticity to study cell response

Summary
In native tissues, the extracellular matrix (ECM) provides not only physical scaffolding to cells, but also biochemical and biomechanical cues affecting cell behaviour. ECM mechanical properties are critical in the regulation of cell behaviour during tissue development, homeostasis and disease via mechano-transduction. Albeit biological tissues generally exhibit a time variant (i.e. dynamic) viscoelastic behaviour that changes during development, ageing and disease, to date most of mechano-transduction studies have focused on static elastic properties only. The ENDYVE project aims at engineering tissue dynamic viscoelasticity typical of pathophysiological processes in-vivo to investigate its role on cell behaviour. Focusing on cardiomyocyte maturation, the viscoelastic properties of foetal, neonatal, aged and infarcted cardiac tissue will
be characterised and used to design cell culture substrates with temporally tuneable mechanical properties that initially mimic foetal viscoelasticity and then can be made more stiff and less viscoelastic during cell culture via a second-step biocompatible enzymatic crosslinking to recapitulate dynamic changes of cardiac viscoelasticity in-vitro. First, stem cell cardiomyocyte behaviour will be investigated at discrete levels of constant viscoelasticity by seeding human induced pluripotent stem cells on substrates prior to and after enzyme-mediated crosslinking. Then the effect of dynamic changes in
substrate viscoelasticity will be characterised during culture. Engineering dynamic viscoelasticity is a critical step towards a better understating of cell-ECM interactions and mechano-transduction, and could lead to the development of new strategies to finely control cell behaviour, with numerous potential societal and clinical implication, such as obtaining mature differentiated cells from stem cells for drug screening in vitro, or limiting, if not preventing, fibrosis and tumour progression.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/705296
Start date: 01-11-2016
End date: 30-06-2018
Total budget - Public funding: 137 999,00 Euro - 137 999,00 Euro
Cordis data

Original description

In native tissues, the extracellular matrix (ECM) provides not only physical scaffolding to cells, but also biochemical and biomechanical cues affecting cell behaviour. ECM mechanical properties are critical in the regulation of cell behaviour during tissue development, homeostasis and disease via mechano-transduction. Albeit biological tissues generally exhibit a time variant (i.e. dynamic) viscoelastic behaviour that changes during development, ageing and disease, to date most of mechano-transduction studies have focused on static elastic properties only. The ENDYVE project aims at engineering tissue dynamic viscoelasticity typical of pathophysiological processes in-vivo to investigate its role on cell behaviour. Focusing on cardiomyocyte maturation, the viscoelastic properties of foetal, neonatal, aged and infarcted cardiac tissue will
be characterised and used to design cell culture substrates with temporally tuneable mechanical properties that initially mimic foetal viscoelasticity and then can be made more stiff and less viscoelastic during cell culture via a second-step biocompatible enzymatic crosslinking to recapitulate dynamic changes of cardiac viscoelasticity in-vitro. First, stem cell cardiomyocyte behaviour will be investigated at discrete levels of constant viscoelasticity by seeding human induced pluripotent stem cells on substrates prior to and after enzyme-mediated crosslinking. Then the effect of dynamic changes in
substrate viscoelasticity will be characterised during culture. Engineering dynamic viscoelasticity is a critical step towards a better understating of cell-ECM interactions and mechano-transduction, and could lead to the development of new strategies to finely control cell behaviour, with numerous potential societal and clinical implication, such as obtaining mature differentiated cells from stem cells for drug screening in vitro, or limiting, if not preventing, fibrosis and tumour progression.

Status

CLOSED

Call topic

MSCA-IF-2015-EF

Update Date

28-04-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.1. EXCELLENT SCIENCE
H2020-EU.1.3. EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions (MSCA)
H2020-EU.1.3.2. Nurturing excellence by means of cross-border and cross-sector mobility
H2020-MSCA-IF-2015
MSCA-IF-2015-EF Marie Skłodowska-Curie Individual Fellowships (IF-EF)